Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Vanzago Italy (2005)

Organization Overview

First Clinical Trial
2005
NCT00813696
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 3)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 20